1. Home
  2. ATYR vs CPAC Comparison

ATYR vs CPAC Comparison

Compare ATYR & CPAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • CPAC
  • Stock Information
  • Founded
  • ATYR 2005
  • CPAC 1949
  • Country
  • ATYR United States
  • CPAC Peru
  • Employees
  • ATYR N/A
  • CPAC N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • CPAC Building Materials
  • Sector
  • ATYR Health Care
  • CPAC Industrials
  • Exchange
  • ATYR Nasdaq
  • CPAC Nasdaq
  • Market Cap
  • ATYR 535.0M
  • CPAC 580.5M
  • IPO Year
  • ATYR 2015
  • CPAC 2012
  • Fundamental
  • Price
  • ATYR $5.63
  • CPAC $6.82
  • Analyst Decision
  • ATYR Strong Buy
  • CPAC Hold
  • Analyst Count
  • ATYR 5
  • CPAC 1
  • Target Price
  • ATYR $23.25
  • CPAC $6.40
  • AVG Volume (30 Days)
  • ATYR 4.3M
  • CPAC 4.6K
  • Earning Date
  • ATYR 11-06-2025
  • CPAC 10-27-2025
  • Dividend Yield
  • ATYR N/A
  • CPAC 7.70%
  • EPS Growth
  • ATYR N/A
  • CPAC 26.68
  • EPS
  • ATYR N/A
  • CPAC 0.14
  • Revenue
  • ATYR N/A
  • CPAC $572,828,408.00
  • Revenue This Year
  • ATYR $478.72
  • CPAC N/A
  • Revenue Next Year
  • ATYR $1,899.26
  • CPAC N/A
  • P/E Ratio
  • ATYR N/A
  • CPAC $9.44
  • Revenue Growth
  • ATYR N/A
  • CPAC 3.37
  • 52 Week Low
  • ATYR $1.67
  • CPAC $5.10
  • 52 Week High
  • ATYR $7.29
  • CPAC $6.90
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 58.33
  • CPAC 60.85
  • Support Level
  • ATYR $5.08
  • CPAC $6.50
  • Resistance Level
  • ATYR $5.77
  • CPAC $6.79
  • Average True Range (ATR)
  • ATYR 0.42
  • CPAC 0.21
  • MACD
  • ATYR 0.02
  • CPAC 0.01
  • Stochastic Oscillator
  • ATYR 66.67
  • CPAC 87.50

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About CPAC Cementos Pacasmayo S.A.A. (Each representing five)

Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.

Share on Social Networks: